PT  - JOURNAL ARTICLE
AU  - Timothy Rinden
AU  - Eric Miller
AU  - Rawad Nasr
TI  - Giant cell arteritis: An updated review of an old disease
AID  - 10.3949/ccjm.86a.18103
DP  - 2019 Jul 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 465--472
VI  - 86
IP  - 7
4099  - http://www.ccjm.org/content/86/7/465.short
4100  - http://www.ccjm.org/content/86/7/465.full
SO  - Cleve Clin J Med2019 Jul 01; 86
AB  - Giant cell arteritis is a common systemic vasculitis that affects the elderly and has a variable clinical presentation. Physicians should be aware of its different clinical phenotypes so that they can recognize it early and promptly initiate glucocorticoids, the mainstay of therapy. Clinicians should also be familiar with the toxicity of glucocorticoids and how to manage adverse effects. Tocilizumab, an interleukin 6 receptor inhibitor, is emerging as a glucocorticoid-sparing treatment, though its long-term safety and efficacy are still under study.